FUNDAMENTALS |
MarketCap: |
23.38 mill
|
EPS: |
-0.0300
|
P/E: |
-0.680
|
Earnings Date: |
May 10, 2024 |
SharesOutstanding: |
1 140.56 mill
|
Avg Daily Volume: |
0.339 mill
|
RATING
2024-05-03 |
C+
|
Sell
|
RATINGS |
Rating CashFlow: |
Sell
|
|
Return On Equity: |
Strong Sell
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Sell
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.680 | sector: PE -11.58
|
PE RATIO: COMPANY / INDUSTRY |
0x
|
Company: PE -0.680 | industry: PE -6.92
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0175 - 0.0235
( +/- 14.63%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-04-01 | Sorensen Peter | Buy | 0 | |
2023-12-30 | Manchester Management Co Llc | Buy | 0 | Future Advance Convertible Promissory Note |
2023-12-30 | Manchester Management Co Llc | Buy | 2 500 000 | Common Stock Purchase Warrant |
2023-12-30 | Manchester Management Co Llc | Buy | 2 500 000 | Common Stock Purchase Warrant |
2023-12-30 | Manchester Management Co Llc | Buy | 2 500 000 | Common Stock Purchase Warrant |
INSIDER POWER |
88.42
|
Last
94 transactions |
Buy:
194 230 063 | Sell:
31 191 675 |
Forecast:
16:00 - $0.0205
Live Trading Signals (every 1 min)
Forecast
1: 15:22 - $0.0200
Forecast 2: 16:00 - $0.0205
Forecast 3: 16:00 - $0.0205
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
Volume Signals |
Price |
$0.0205 (-10.87% )
|
Volume |
0.350 mill
|
Avg. Vol. |
0.339 mill
|
% of Avg. Vol |
103.22 %
|
Signal 1: |
|
Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SNWV
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.